Tong Liao Shi

Researchers are studying whether using a drug-eluting stent DES combined with aggressive medical treatment is more effective at preventing stroke recurrence within one year compared to standard medical treatment alone in patients with symptomatic intracranial atherosclerotic disease. This prospective, multi-center trial randomly assigns participants to either the stent plus aggressive medication group or the standard treatment group to evaluate safety and stroke prevention outcomes. The study compares two groups one receiving the Maurora Sirolimus Eluting Stent implantation plus aggressive medical treatment, which includes aspirin daily throughout follow-up, clopidogrel or ticagrelor for six months, and management of risk factors like hypertension and diabetes the other receiving standard medical treatment with aspirin daily, clopidogrel or ticagrelor for three months, and similar risk factor management. The device used is a balloon-expandable sirolimus-eluting stent delivered via catheter. Follow-up lasts 12 months after enrollment. Participants will undergo regular assessments including monitoring for stroke or death within 30 days after enrollment or procedures, ischemic stroke occurrence up to one year, bleeding events, imaging to check for vessel narrowing, and functional status evaluations. Safety and effectiveness are closely tracked through clinical visits and tests over the 12-month period. The study aims to provide detailed data on stroke recurrence prevention and treatment safety in this patient population.

Acute ischemic stroke is a leading cause of death worldwide, and intravenous thrombolysis with recombinant tissue plasminogen activator rt-PA within 4.5 hours of symptom onset is the most effective treatment currently available. However, some patients experience stroke progression and early reocclusion after thrombolysis, which can worsen neurological outcomes. This trial evaluates whether early antiplatelet therapy with oral aspirin, given soon after thrombolysis, can improve recovery without increasing bleeding risks. The study randomly assigns patients to receive either early oral aspirin within 3 hours of starting intravenous thrombolysis or a placebo, alongside the best medical care based on current guidelines. Aspirin is administered as a 300 mg dose, either chewed or given via nasogastric tube if swallowing is difficult. The trial includes a control group receiving placebo under similar conditions to compare outcomes. This is a Phase 3, multicenter, quadruple-blind, randomized clinical trial. During the study, participants will be closely monitored for neurological status and functional recovery using the modified Rankin scale at 30 and 90 days after stroke, as well as other assessments like NIH Stroke Scale scores within the first week. Researchers will track early neurological changes and safety outcomes such as intracranial hemorrhage. Follow-up will include evaluations at multiple time points up to 90 days post-stroke to determine the effects of early antiplatelet treatment on stroke recovery.

Chronic obstructive pulmonary disease COPD is a common long-term respiratory condition often accompanied by other health problems. This research aims to gather real-world data on managing COPD alongside these additional conditions using a combination of Chinese and Western medicine approaches. The study focuses on understanding risk factors for high-risk groups and patients with confirmed comorbidities, developing models to predict risks of comorbidities and acute COPD flare-ups, and improving long-term care strategies with early detection across hospitals, communities, and homes. Participants will receive routine clinical care following current guidelines, with no study-mandated treatments assigned. Data will be collected through standard clinical evaluations such as symptom questionnaires, lung function tests, imaging, and biomarker analysis. Additionally, continuous multisensor digital monitoring will track heart rate, blood pressure, activity, sleep, and other physiological and behavioral signs. Traditional Chinese Medicine assessments including tongue, pulse, and facial diagnostics will also be performed to provide comprehensive digital phenotyping. Throughout the study, participants will be regularly assessed by clinical tests, questionnaires, and continuous monitoring devices. Researchers will measure the annual rate of COPD exacerbations and the occurrence of related comorbidities such as hypertension, heart disease, arrhythmia, heart failure, and diabetes over up to 36 months. This extensive monitoring aims to support evidence-based management and early warning systems for COPD with comorbidities. The total study duration and follow-up will be up to three years.

Obesity greatly increases the risk of heart failure, and current treatments like caloric restriction, exercise, medications, or surgery may not be suitable for obese patients with heart failure. This research aims to study whether a combined approach using a diet management app and an intelligent weight scale can help obese patients with heart failure and reduced ejection fraction lose weight and improve their heart condition. The trial compares the effectiveness of a fully functional app and scale versus a limited-function version to assess their impact on heart failure outcomes and overall quality of life. Participants are randomly assigned to two groups one using a fully featured diet management app and intelligent weight scale with various monitoring tools and health metrics, and the other using a limited version of both. The full app tracks food intake, exercise, weight, and provides dietary analysis and recommendations, while the full scale measures body composition and vital signs. The limited versions offer fewer features. Participants use the app at every meal and weigh themselves daily for 12 months. During the study, participants will visit the clinic at 12 months for checkups. Researchers will evaluate outcomes such as a composite of death and heart failure hospitalizations over one year, changes in quality of life related to heart failure, and weight change. The trial includes monitoring of heart failure frailty and quality of life assessments at baseline, 3 months, and 1 year, with ongoing safety and condition tracking throughout the study period.

Researchers are comparing the safety and effectiveness of two intravenous drugs, urokinase and alteplase, in treating acute ischemic stroke AIS within 6 hours of symptom onset. Alteplase is currently recommended within 4.5 hours but is costly, while urokinase is less expensive. Existing studies show mixed results for urokinase, so this study aims to gather real-world data on both treatments, including safety, effectiveness, and economic impact, to help inform future stroke care. The study involves patients receiving either intravenous urokinase or alteplase as treatment for AIS. Researchers will observe and analyze these treatments in multiple centers across the nation, comparing outcomes and exploring different urokinase dosages and related risk factors. Alteplase serves as the active control group to evaluate urokinase against current standards. Participants will be monitored for their functional recovery using the modified Rankin scale at 90 days after treatment to assess good outcomes. The study includes clinical diagnosis confirmation, imaging to exclude hemorrhage, and patient consent procedures. Data on safety, effectiveness, and costs will be collected, with follow-up assessments at day 90. The trial aims to provide comprehensive information over its duration until December 2026.